Results
Out of 73 patients, 24 patients are included in ilaprazole group (IPL) and 49
patients are included in rabeprazole group (RPL). Based on the exclusion criteria 28
patients from rabeprazole group and 3 patients from ilaprazole group are excluded because
of their noncompliance with the treatment regimen. A total of 41 patients are included in
study of which 21 are female, 20 are male.
EFFICACY ASSESSMENT:
ULCER HEALING:
After 40 days of PPI's regimen, amongst 21 patients who were treated with rabeprazole
and 20 patients treated with the ilaprazole, the patients who did not show completely
healed endoscopical results would be 2 (9.52%) and 3 (15%) respectively.
Fig No.1:
25
20
15
10
5
0
IPL (B)
GIET School of Pharmacy
IPL (E)
RPL (B)
RPL(E)
32
Results
SYMPTOMS RELIEF:
ABDOMINAL PAIN:
Amongst 41 patients, 16 were severe, 21were moderate, 1was showing low and 3 were
showing no pain prior to treatment. In the ilaprazole group, patients have shown moderate,
low and no pain at 10%, 30%, 60% respectively. Whereas in rabeprazole group, patients
have shown moderate, low and no pain at 9.5%, 23.8%, 66.6% respectively. None of the
patients show severe pain.
Table No: 1
Abdominal Pain
Low
Moderate
Severe
No
Ilaprazole(B) Ilaprazole (E)
0
30%
50%
10%
45%
0
5%
60%
Rabeprazole(B)
4.7%
52.3%
33.3%
9.5%
Rabeprazole(E)
23.8%
9.5%
0
66.6%
Fig No.2:
0.7
0.6
0.5
Low
0.4
Moderate
0.3
Severe
No
0.2
0.1
0
IPL (B)
GIET School of Pharmacy
IPL ( E)
RPL (B)
RPL ( E)
33
Results
DISCOMFORT:
Amongst 41 patients, 19.5% were showing discomfort prior to treatment. In the
ilaprazole and rabeprazole groups, patients, who were free of discomfort were 90% and
80.9% respectively.
Table No:2
Discomfort
Yes
No
Ilaprazole (B)
15%
85%
Ilaprazole (E)
10%
90%
Rabeprazole(B)
23.8%
76.1%
Rabeprazole(E)
19%
80.9%
Fig No.3:
90%
80%
70%
60%
50%
Yes
40%
No
30%
20%
10%
0%
IPL (B)
GIET School of Pharmacy
IPL (E)
RPL (B)
RPL( E)
34
Results
HEART BURN:
Amongst 41 patients, 39% were reported with heart burn prior to treatment. In the
ilaprazole and rabeprazole groups, patients who shown relief of heart burn are 90% and
95.2% respectively.
Table No:3
Heart Burn
Yes
No
Ilaprazole(B)
30
70
Ilaprazole(E)
10
90
Rabeprazole(B)
47.6
52.3
Rabeprazole(E)
4.7
95.2
Fig No.4:
100
90
80
70
60
Yes
50
No
40
30
20
10
0
IPL (B)
GIET School of Pharmacy
IPL (E)
RPL (B)
RPL (E)
35
Results
BELCHING:
Amongst 41 patients, 21.9% were reported belching prior to treatment. In the ilaprazole
and rabeprazole groups, patients who were relief of belching are 90% and 90.4%
respectively.
Table No: 4
Belching
Yes
No
Ilaprazole (B)
20%
80%
Ilaprazole (E)
10%
90%
Rabeprazole(B)
23.8%
76.1%
Rabeprazole(E)
9.5%
90.4%
Fig No.5:
100%
90%
80%
70%
60%
Yes
50%
No
40%
30%
20%
10%
0%
IPL (B)
GIET School of Pharmacy
IPL (E)
RPL (B)
RPL (E)
36
Results
PAIN AT NIGHT:
Amongst 41 patients, 43.9% were reported pain at night prior to treatment. In the
ilaprazole and rabeprazole groups, patients who were relief of pain at night 90% and
95.2% respectively.
Table No: 5
Pain at night
Yes
No
Ilaprazole (B)
50%
50%
Ilaprazole (E)
10%
90%
Rabeprazole(B)
38.09%
61.9%
Rabeprazole(E)
4.7%
95.2%
Fig No.6:
100%
90%
80%
70%
60%
Yes
50%
No
40%
30%
20%
10%
0%
IPL (B)
GIET School of Pharmacy
IPL (E)
RPL (B)
RPL (E)
37
Results
REDUCED APPETITE:
Amongst 41 patients, 26.82% were reported loss of appetite prior to treatment. In the
ilaprazole and rabeprazole groups, patients who have shown improved appetite are 90%
and 80.95% respectively.
Table No: 6
Reduced Appetite
Yes
No
Ilaprazole
(B)
20%
80%
Ilaprazole
(E)
10%
90%
Rabeprazole
(B)
33.33%
66.66%
Rabeprazole
(E)
19.04%
80.95%
Fig No.7:
90%
80%
70%
60%
50%
Yes
40%
No
30%
20%
10%
0%
IPL (B)
GIET School of Pharmacy
IPL (E)
RPL (B)
RPL (E)
38
Results
NAUSEA:
Amongst 41 patients, 60.97% were reported nausea prior to treatment. In the ilaprazole
and rabeprazole groups, patients who have shown improved nauseated feeling are 70%
and 76.19% respectively.
Table No: 7
Nausea
Yes
No
Ilaprazole (B)
75
25
Ilaprazole (E)
30
70
Rabeprazole(B)
47.61
52.38
Rabeprazole(E)
23.8
76.19
Fig No.8:
80
70
60
50
Yes
40
No
30
20
10
0
IPL (B)
GIET School of Pharmacy
IPL (E)
RPL (B)
RPL (E)
39
Results
SAFETY AND TOLERANCE:
Observations in the study showed that ilaprazole and rabeprazole are well tolerated.
The main adverse events occurred in this study are diarrhoea and constipation. In the
ilaprazole group
2(10%) patients experienced constipation and 1(4.7%) patient
experienced diarrhoea whereas in rabeprazole group 1(5%) patients experienced
constipation and 1(4.7%) patient experienced diarrhoea.
Table No: 8
Diarrhoea
Yes
No
Ilaprazole(B)
0
100
Ilaprazole(E)
5
95
Fig No.9:
Rabeprazole(B)
0
100
Rabeprazole(E)
4.7
95.2
100
80
60
Yes
40
No
20
0
IPL (B)
IPL (E)
RPL (B)
RPL (E)
Table No: 9
Constipation
Yes
No
Ilaprazole(B)
5
95
Ilaprazole(E) Rabeprazole(B)
15
4.7
85
95.23
Fig No.10:
Rabeprazole(E)
9.5
90.47
100
80
60
Yes
40
No
20
0
IPL (B)
GIET School of Pharmacy
IPL (E)
RPL (B)
RPL (E)
40
